

Mangalam Drugs and Organics Limited

Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-62616200 / 6300 / 8787 ☎ 91-22-62619090 • CIN : L24230MH1972PLC116413



August 26, 2024

REF: MDOL/CS-SE/2024-25/019

To,

Listing Department

BSE Ltd

1st Floor, New Trade Wing,

Phiroze Jeejeebhoy Towers,

Dalal Street, Fort,

Mumbai – 400 001

Scrip Code: 532637

Listing Department

National Stock Exchange of India Limited

“Exchange Plaza”, 5th Floor,

Plot No. C-1, Block G,

Bandra - Kurla Complex,

Bandra (E), Mumbai – 400 051

Symbol: MANGALAM

SUBJECT: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR").

Dear Sir / Madam,

In accordance with Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as well as SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, we are pleased to announce that Mangalam Drugs & Organics Limited has been awarded a grant by The Medicines for Malaria Venture (“MMV”). The grant amounts to USD 274,800\$ and is designated for the research and development of Pyronaridine.

The Medicines for Malaria Venture (MMV), headquartered in Geneva, Switzerland, is a non-profit organization committed to the development and support of innovative antimalarial therapies. MMV focuses on advancing new treatments for malaria and optimizing combination therapies. The pyronaridine-artesunate combination therapy, endorsed by MMV, leverages the synergistic effects of both drugs to enhance therapeutic efficacy in combating malaria.

Mangalam Drugs and Organics Limited



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-62616200 / 6300 / 8787 ☎ 91-22-62619090 • CIN : L24230MH1972PLC116413

The grant will support research and development efforts aimed at improving the technology and efficiency of pyronaridine production. With an estimated international market size to reach 50 million treatments in the next few years., Mangalam Drugs & Organics Limited plans to commercialize this product by the end of 2024 which will position the company at the forefront of global anti-malaria API production and performances.

Kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For

Mangalam Drugs & Organics Limited

Govardhan M. Dhoot

Managing Director

DIN : 01240086

Place : Mumbai